Nuvation Bio Inc. (NUVB)
NYSE NYSE Primary Summary
Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy
Nuvation Bio earns a modest Buy at ~$5, supported by the steady adoption of IBTROZI, its lead asset, by patients and prescribers alike during the last 7 months. IBTROZI's patient starts stabilized at 3.3/day in late 2025, with revenue projections reaching ~$1B by 2030 based upon conservative assumptions. NUVB holds ~$620M in cash, sufficient to reach profitability, minimizing near-term dilution risk as rollout continues.
Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Nuvation Bio Inc. (NUVB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround
Nuvation Bio (NUVB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Nuvation Bio Inc. (NUVB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Nuvation Bio Inc. ever had a stock split?
Nuvation Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | David T. Hung CEO | NYSE Exchange | 67080N101 CUSIP |
| US Country | 273 Employees | - Last Dividend | - Last Split | 24 Aug 2020 IPO Date |
Overview
Nuvation Bio Inc. operates as a clinical-stage biopharmaceutical entity, dedicating its efforts toward the development of novel therapeutic candidates primarily in the field of oncology. Founded in 2018, the company is based in New York, New York, positioning itself as a pioneer in advancing cancer treatment options. Through its focus on cutting-edge research and development, Nuvation Bio Inc. aims to address the unmet medical needs in cancer care by leveraging its expertise in biopharmaceutical innovation to create a significant impact on patients' lives.
Products and Services
- NUV-868
As the lead product candidate of Nuvation Bio Inc., NUV-868 is a BD2 selective oral small molecule BET inhibitor. This innovative therapy works through epigenetic regulation of proteins pivotal in tumor growth and differentiation, including key oncogenes like c-myc. By targeting BET proteins, NUV-868 aims to disrupt the cancer cell cycle, providing a novel avenue for cancer treatment.
- NUV-1156
NUV-1156 represents another cornerstone of Nuvation Bio's portfolio. It is an AR binder Xtandi designed to tackle advanced-stage prostate cancers. This product has the unique potential to be used in earlier lines of treatment that typically involve surgical prostatectomy, offering a less invasive option for patients. By focusing on advanced prostate cancer, NUV-1156 could fill a significant treatment gap in current cancer care practices.
- Drug-Drug Conjugate (DDC) Platform
The Drug-Drug Conjugate platform developed by Nuvation Bio brings a novel approach to the drug-conjugate class of anti-cancer therapies. This technology aims to deliver anti-cancer therapeutics directly to cancer cells, ensuring more targeted treatment modalities with potentially reduced side effects. The DDC platform exemplifies Nuvation Bio's commitment to innovation in drug delivery systems for oncology.
- NUV-1176
A part of the company's diverse oncology pipeline, NUV-1176 is a PARP inhibitor focused on addressing ER+ breast and ovarian cancer. By leveraging the mechanism of PARP inhibition, NUV-1176 seeks to exploit the innate vulnerabilities of cancer cells, thereby offering a potentially effective treatment option for patients suffering from these types of cancer.
